149. Hemiconvulsion hemiplegia epilepsy syndrome
[
16 clinical trials,
22 drugs（DrugBank:
10 drugs),
6 target genes / 10 target pathways ]
Searched query = "Hemiconvulsion hemiplegia epilepsy syndrome", "One side convulsions", "Hemiplegia", "Epilepsy syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194958 | 01/10/2019 | 7 October 2019 | A pharmacokinetic, safety, and tolerability study of padsevonil in CYP2C19 genotyped healthy male Japanese study participants. | An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants | Epilepsy and epilepsy syndrome | Intervention name : padsevonil INN of the intervention : padsevonil Dosage And administration of the intervention : Oral administration Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | Recruiting | 20 | 55 | Male | 39 | Phase 1 | Japan | |
| 2 | JPRN-JapicCTI-194633 | 05/6/2019 | 7 October 2019 | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | Patients with upper limb hemiplegia after cerebral infarction or cerebral hemorrhage (other than subarachnoid hemorrhage) | Intervention name : T-817MA INN of the intervention : Edonerpic Dosage And administration of the intervention : Oral Multiple Dose Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | FUJIFILM Toyama Chemical Co., Ltd | Recruiting | 20 | 79 | BOTH | 45 | Phase 2 | Japan | |
| 3 | JPRN-jRCTs042190020 | 22/04/2019 | 22 July 2019 | The Effectiveness of BEAR for hemiplegic patients | The Effectiveness of Balance Exercise Assist Robot for convalescent patients with hemiplegia after stroke - EBEARCPHAS | Stroke | Using Balance Exercise Assist Robot | Eiichi Saitoh | Recruiting | >=20 age old | <90 age old | Both | 60 | N/A | none | |
| 4 | NCT03860662 | February 26, 2019 | 18 March 2019 | Nociceptive Flexor Reflex and Antispastic Treatmens | Research Assistant Doctor | Stroke Sequelae;Spastic Hemiplegia | Diagnostic Test: Nociceptor flexor reflex;Drug: Botox;Drug: Baclofen | Mustafa Kemal University | Not recruiting | 18 Years | 60 Years | All | 30 | Phase 4 | Turkey | |
| 5 | JPRN-JapicCTI-184137 | 04/1/2019 | 5 November 2019 | A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replaement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age with Partial Seizures With or Without Secondary Generalization | A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replaement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age with Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : brivaracetam INN of the intervention : brivaracetam Dosage And administration of the intervention : Intravenous (iv) injection Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | Recruiting | 16 | BOTH | 10 | Phase 3 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-JapicCTI-173615 | 22/8/2017 | 5 November 2019 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : ucb 34714 INN of the intervention : Brivaracetam Dosage And administration of the intervention : Oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | Recruiting | 16 | 80 | BOTH | 504 | Phase 3 | Japan, Asia except Japan | |
| 7 | JPRN-JapicCTI-173687 | 05/8/2017 | 5 November 2019 | An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization | An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : brivaracetam INN of the intervention : brivaracetam Dosage And administration of the intervention : Oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | Recruiting | 16 | BOTH | 124 | Phase 3 | Japan | ||
| 8 | JPRN-JapicCTI-153103 | 08/12/2015 | 5 November 2019 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | Epilepsy and epilepsy syndrome | Intervention name : SPM927 INN of the intervention : Lacosamide Dosage And administration of the intervention : oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | Not Recruiting | 4 | BOTH | 242 | Phase 3 | Japan, Asia except Japan, North America, Europe, Oceania | ||
| 9 | NCT02455232 | May 2015 | 16 December 2017 | Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients | Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients | Hemiplegia | Procedure: upper limb muscle block;Drug: 4cc of lidocaïne® | Centre d'Investigation Clinique et Technologique 805 | Not recruiting | 18 Years | 75 Years | All | 20 | N/A | France | |
| 10 | NCT02408354 | March 2015 | 16 December 2017 | Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood | Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant HEMIHEP | Alternating Hemiplegia of Childhood | Drug: Triheptanoin;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | Not recruiting | 15 Years | N/A | All | 10 | Phase 2 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | ChiCTR-ICR-15007022 | 2014-05-01 | 18 April 2017 | A research of biomechanic stimulation and healing of hemiplegia gait | A research of biomechanic stimulation and healing of hemiplegia gait | stroke | botulinum toxin A type group:inject botulinum toxin A type;conventional treatment A group :conventional treatment;Dynamic electrical stimulation treatment group:Dynamic electrical stimulation;conventional treatment B group :conventional treatment;blank control group:null;validation group :botulinum toxin A type ; | Nanjing Sports Institude | Recruiting | 40 | 70 | Both | botulinum toxin A type group:30;conventional treatment A group :30;Dynamic electrical stimulation treatment group:30;conventional treatment B group :30;blank control group:30;validation group :30; | New Treatment Measure Clinical Study | China | |
| 12 | NCT01623622 | July 2012 | 16 December 2017 | Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke | A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke | Severe Upper Limb Hemiplegia | Drug: HC-58;Drug: Placebo | Asahi Kasei Pharma Corporation | Not recruiting | 20 Years | N/A | All | 270 | Phase 2 | Japan | |
| 13 | EUCTR2009-015620-29-BE | 08/03/2010 | 7 October 2014 | The efficacy of the Botulinum toxin-A on the manual abilities in children with congenital spastic hemiplegia. Interest of the measure of the bimanual task performance. | The efficacy of the Botulinum toxin-A on the manual abilities in children with congenital spastic hemiplegia. Interest of the measure of the bimanual task performance. | The main objective of this study is to investigate the effect of Botulinum toxin A to improve the Upper Limb dysfunction in Hemiplegic Cerebral Palsy Children and in particular, its impact on Upper limb activity performance and how this might be translate in bimanual activities. MedDRA version: 12.0 Level: LLT Classification code 10019475 Term: Hemiplegic infantile cerebral palsy | Trade Name: BOTOX Product Name: BOTOX Product Code: 9060X Pharmaceutical Form: Injection* CAS Number: 93384-43-1 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use | Authorised | Female: yes Male: yes | 30 | Belgium | |||||
| 14 | NCT00931164 | August 2009 | 19 October 2017 | Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) | Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial) | Alternating Hemiplegia of Childhood | Drug: Sodium Oxybate | University of Utah | Alternating Hemiplegia of Childhood Foundation;Jazz Pharmaceuticals | Not recruiting | 6 Months | 25 Years | All | 6 | Phase 1/Phase 2 | United States |
| 15 | NCT00632528 | March 2008 | 19 February 2015 | MEOPA to Improve Physical Therapy Results After Multilevel Surgery | Evaluation of the Efficacy of MEOPA Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia. | Cerebral Palsy;Spastic Diplegia;Quadriplegia;Hemiplegia | Drug: MEOPA;Drug: Medicinal air | Assistance Publique - Hôpitaux de Paris | Not recruiting | 6 Years | 20 Years | Both | 64 | Phase 3 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00276185 | December 2005 | 19 February 2015 | HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke | Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke | Hemiplegia | Drug: Time delay treatment of botulinum toxin | University Hospital, Clermont-Ferrand | J. Rebeyrol Hospital in Limoges;Rennes University Hospital;Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes);Saint Jacques Hospital in Nantes;Centre Hospitalier Universitaire de Saint Etienne;Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers;Centre Hospitalier Universitaire de Besancon | Recruiting | 18 Years | N/A | Both | 180 | Phase 3 | France |